癌症患者完全植入式静脉输液港相关静脉血栓栓塞风险:系统评价与Meta分析
该系统评价与Meta分析共纳入80项研究、39 148例患者,评估完全植入式静脉输液港(TIVAP)相关静脉血栓栓塞(VTE)发生率。非对照研究中症状性VTE总体发生率为2.76%(95%CI 2.24-3.28),经上肢静脉置入时最高(3.54%,95%CI 2.94-4.76)。病例对照研究显示TIVAP较经外周置入中心静脉导管VTE风险降低(OR=0.20,95%CI 0.09-0.43),较Hickman导管呈降低趋势(OR=0.75,95%CI 0.37-1.50)。
要点
- 非对照研究中TIVAP相关症状性VTE总体发生率为2.76%(95%CI 2.24-3.28)。
- 经上肢静脉置入TIVAP时VTE发生率最高,为3.54%(95%CI 2.94-4.76)。
- TIVAP较经外周置入中心静脉导管VTE风险降低(OR=0.20,95%CI 0.09-0.43)。
核心结论
- 当前证据提示,与外部中心静脉导管相比,携带TIVAP的癌症患者发生VTE的可能性较低,选择化疗留置静脉装置时应考虑这一点。
- 选择上肢静脉作为置入部位时应给予更多关注。
研究设计与样本
- 系统评价与Meta分析,从医学文献数据库检索报告TIVAP相关VTE风险的研究。
- 共纳入80项研究(11项有对照组、69项无对照组),包括39 148例患者。
- 无对照组的研究计算TIVAP相关VTE的合并发生率;有对照组的研究计算比值比(OR)以评估VTE风险。
主要发现
- 非对照研究中症状性VTE总体发生率为2.76%(95%CI 2.24-3.28),每1000导管日为0.08(95%CI 0.06-0.10)。
- 经上肢静脉置入TIVAP时VTE风险最高,为3.54%(95%CI 2.94-4.76)。
- 病例对照研究的Meta分析显示,与经外周置入中心静脉导管相比,TIVAP与VTE风险降低相关(OR=0.20,95%CI 0.09-0.43)。
- 与Hickman导管相比,TIVAP的VTE风险呈降低趋势(OR=0.75,95%CI 0.37-1.50)。
- Meta回归模型提示,地域差异可能显著影响TIVAP相关VTE的发生率。
临床怎么用
- 作者认为,选择化疗留置静脉装置时应考虑携带TIVAP的癌症患者发生VTE的可能性较低这一证据。
- 作者指出,选择上肢静脉作为置入部位时应给予更多关注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Totally implantable venous access ports (TIVAPs) for chemotherapy are associated with venous thromboembolism (VTE). We aimed to quantify the incidence of TIVAP-associated VTE and compare it with external central venous catheters (CVCs) in cancer patients through a meta-analysis. METHODS: Studies reporting on VTE risk associated with TIVAP were retrieved from medical literature databases. In publications without a comparison group, the pooled incidence of TIVAP-related VTE was calculated. For studies comparing TIVAPs with external CVCs, odds ratios (ORs) were calculated to assess the risk of VTE. RESULTS: In total, 80 studies (11 with a comparison group and 69 without) including 39 148 patients were retrieved. In the noncomparison studies, the overall symptomatic VTE incidence was 2.76% (95% confidence interval [CI]: 2.24-3.28), and 0.08 (95 CI: 0.06-0.10) per 1000 catheter-days. This risk was highest when TIVAPs were inserted via the upper-extremity vein (3.54%, 95% CI: 2.94-4.76). Our meta-analysis of the case-control studies showed that TIVAPs were associated with a decreased risk of VTE compared with peripherally inserted central catheters (OR = 0.20, 95% CI: 0.09-0.43), and a trend for lower VTE risk compared with Hickman catheters (OR = 0.75, 95% CI: 0.37-1.50). Meta-regression models suggested that regional difference may significantly impact on the incidence of VTE associated with TIVAPs. CONCLUSIONS: Current evidence suggests that the cancer patients with TIVAP are less likely to develop VTE compared with external CVCs. This should be considered when choosing the indwelling intravenous device for chemotherapy. However, more attention should be paid when choosing upper-extremity veins as the insertion site.
引用
- Jiang M, Li CL, Pan CQ, et al. Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32479699. doi:10.1111/jth.14930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。